Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low socioeconomic position is a risk factor for delay to treatment and mortality of testicular cancer patients in Hungary, a prospective study.
Küronya Z, Fröhlich G, Ladányi A, Martin T, Géczi L, Gyergyai F, Horváth O, Kiszner G, Kovács Á, Dienes T, Lénárt E, Nagyiványi K, Szarvas T, Szőnyi M, Tóth A, Biró K. Küronya Z, et al. BMC Public Health. 2021 Sep 19;21(1):1707. doi: 10.1186/s12889-021-11720-w. BMC Public Health. 2021. PMID: 34538241 Free PMC article.
[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Biró K, Küronya Z. Biró K, et al. Among authors: kuronya z. Magy Onkol. 2010 Dec;54(4):369-76. doi: 10.1556/MOnkol.54.2010.4.11. Magy Onkol. 2010. PMID: 21163768 Free article. Review. Hungarian.
In cytokine refractory patients, sorafenib, when patients have progressed on a tyrosine kinase inhibitor everolimus is the agent of choice. Biro K, Kuronya Z. Recent advancements in the treatment of renal cell carcinoma - focus on international guidelines....
In cytokine refractory patients, sorafenib, when patients have progressed on a tyrosine kinase inhibitor everolimus is the agent of choice. …
[Treatment strategies for advanced prostate cancer].
Küronya Z, Bíró K, Géczi L, Németh H. Küronya Z, et al. Magy Onkol. 2015 Sep;59(3):229-40. Epub 2015 May 26. Magy Onkol. 2015. PMID: 26339912 Free article. Review. Hungarian.
[Immunotherapy in the treatment of genitourinary cancers].
Géczi L, Ladányi A, Vajdics T, Küronya Z, Bíró K, Gyergyay F, Martin T, Nagyiványi K. Géczi L, et al. Among authors: kuronya z. Magy Onkol. 2016 Mar 2;60(1):41-5. Epub 2016 Feb 8. Magy Onkol. 2016. PMID: 26934350 Free article. Review. Hungarian.
49 results